SOPHiA GENETICS reports Q2 2026 revenue of $23.3 million, raises 2026 outlook to $94 million–$96 million
AI Market Summary
SOPHiA GENETICS reported Q2'26 revenue of $23.3m (+27% y/y) with improving adjusted EBITDA loss (-27% y/y to $8.8m) and raised FY'26 revenue guidance to $94–96m. U.S. volumes grew 60% and liquid biopsy revenue rose 80%, reinforcing demand for precision oncology analytics. While still loss-making, the guidance lift and new BioPharma CDx programs with AstraZeneca support positive risk sentiment toward genomics/healthcare themes.
Impact level
● Low
Affected assets
NCSKONDS2USD/USDT+8.80%
AI Insight · NCSKONDS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
SOPHiA GENETICS reported second-quarter 2026 revenue of $23.3 million, up 27% year over year, with a reported gross margin of 64.6%. Net loss was $22.4 million, flat year over year, while adjusted EBITDA loss narrowed 27% to $8.8 million. The company raised its 2026 revenue guidance to $94 million–$96 million, and said U.S. analysis volume rose 60% year over year, according to the company.
